Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

The tyrosine phosphatase TC48 interacts with and inactivates the oncogenic fusion protein BCR-Abl but not cellular Abl.

Mitra A, Sasikumar K, Parthasaradhi BV, Radha V.

Biochim Biophys Acta. 2013 Jan;1832(1):275-84. doi: 10.1016/j.bbadis.2012.10.014. Epub 2012 Oct 31.

2.

Emerging role of tyrosine phosphatase, TCPTP, in the organelles of the early secretory pathway.

Muppirala M, Gupta V, Swarup G.

Biochim Biophys Acta. 2013 May;1833(5):1125-32. doi: 10.1016/j.bbamcr.2013.01.004. Epub 2013 Jan 15. Review.

3.

PTPROt inactivates the oncogenic fusion protein BCR/ABL and suppresses transformation of K562 cells.

Motiwala T, Majumder S, Ghoshal K, Kutay H, Datta J, Roy S, Lucas DM, Jacob ST.

J Biol Chem. 2009 Jan 2;284(1):455-64. doi: 10.1074/jbc.M802840200. Epub 2008 Nov 7.

4.

TC-PTP dephosphorylates the guanine nucleotide exchange factor C3G (RapGEF1) and negatively regulates differentiation of human neuroblastoma cells.

Mitra A, Kalayarasan S, Gupta V, Radha V.

PLoS One. 2011;6(8):e23681. doi: 10.1371/journal.pone.0023681. Epub 2011 Aug 18.

5.
6.

Protein tyrosine phosphatase 1B antagonizes signalling by oncoprotein tyrosine kinase p210 bcr-abl in vivo.

LaMontagne KR Jr, Flint AJ, Franza BR Jr, Pandergast AM, Tonks NK.

Mol Cell Biol. 1998 May;18(5):2965-75.

7.

Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.

Koch A, Scherr M, Breyer B, Mancini A, Kardinal C, Battmer K, Eder M, Tamura T.

Oncogene. 2008 Aug 7;27(34):4678-89. doi: 10.1038/onc.2008.107. Epub 2008 Apr 21.

PMID:
18427551
8.

Inhibition of phosphotyrosine phosphatase 1B causes resistance in BCR-ABL-positive leukemia cells to the ABL kinase inhibitor STI571.

Koyama N, Koschmieder S, Tyagi S, Portero-Robles I, Chromic J, Myloch S, N├╝rnberger H, Rossmanith T, Hofmann WK, Hoelzer D, Ottmann OG.

Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2025-31.

9.

Regulation of insulin receptor signaling by the protein tyrosine phosphatase TCPTP.

Galic S, Klingler-Hoffmann M, Fodero-Tavoletti MT, Puryer MA, Meng TC, Tonks NK, Tiganis T.

Mol Cell Biol. 2003 Mar;23(6):2096-108.

10.

Tyrosine phosphorylation and activation of focal adhesion kinase (p125FAK) by BCR-ABL oncoprotein.

Gotoh A, Miyazawa K, Ohyashiki K, Tauchi T, Boswell HS, Broxmeyer HE, Toyama K.

Exp Hematol. 1995 Oct;23(11):1153-9.

PMID:
7556524
11.

Jak2 is involved in c-Myc induction by Bcr-Abl.

Xie S, Lin H, Sun T, Arlinghaus RB.

Oncogene. 2002 Oct 17;21(47):7137-46.

12.
13.

The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3' kinase pathway.

Sattler M, Salgia R, Okuda K, Uemura N, Durstin MA, Pisick E, Xu G, Li JL, Prasad KV, Griffin JD.

Oncogene. 1996 Feb 15;12(4):839-46.

PMID:
8632906
14.

Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation.

Xie S, Wang Y, Liu J, Sun T, Wilson MB, Smithgall TE, Arlinghaus RB.

Oncogene. 2001 Sep 27;20(43):6188-95.

15.

Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.

O'Hare T, Pollock R, Stoffregen EP, Keats JA, Abdullah OM, Moseson EM, Rivera VM, Tang H, Metcalf CA 3rd, Bohacek RS, Wang Y, Sundaramoorthi R, Shakespeare WC, Dalgarno D, Clackson T, Sawyer TK, Deininger MW, Druker BJ.

Blood. 2004 Oct 15;104(8):2532-9. Epub 2004 Jul 15.

16.

Regulation of the c-Abl and Bcr-Abl tyrosine kinases.

Hantschel O, Superti-Furga G.

Nat Rev Mol Cell Biol. 2004 Jan;5(1):33-44. Review.

PMID:
14708008
18.

Single-cell analysis of K562 cells: an imatinib-resistant subpopulation is adherent and has upregulated expression of BCR-ABL mRNA and protein.

Karimiani EG, Marriage F, Merritt AJ, Burthem J, Byers RJ, Day PJ.

Exp Hematol. 2014 Mar;42(3):183-191.e5. doi: 10.1016/j.exphem.2013.11.006. Epub 2013 Nov 20.

PMID:
24269846
19.

Bcr: a negative regulator of the Bcr-Abl oncoprotein.

Wu Y, Ma G, Lu D, Lin F, Xu HJ, Liu J, Arlinghaus RB.

Oncogene. 1999 Aug 5;18(31):4416-24.

20.

Bcr and Abl interaction: oncogenic activation of c-Abl by sequestering Bcr.

Ling X, Ma G, Sun T, Liu J, Arlinghaus RB.

Cancer Res. 2003 Jan 15;63(2):298-303.

Supplemental Content

Support Center